SignalFDA/Bio

Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical

$105M debt conversion clears balance sheet, but Phase 3 partnership remains critical catalyst.

What changed

$105M debt conversion clears balance sheet, but Phase 3 partnership remains critical catalyst.

Why it matters

$105M debt conversion clears balance sheet, but Phase 3 partnership remains critical catalyst. — impact context not separately stored; see What changed.

Sources

seekingalpha